Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ghawar cycling more water as expected. SA production is now spread amongst 101 fields compared to a few dozen a couple of decades ago.
https://www.bloomberg.com/news/articles/2019-04-02/saudi-aramco-reveals-sharp-output-drop-at-super-giant-oil-field
Most take public transportation, hire taxis and private client drivers/cars. Car ownership is an expensive privilege like in other major Asian cities. Singapore is like that too. It is probably the same in major Chinese cities.
https://www.scmp.com/property/hong-kong-china/article/2141997/what-costs-more-apartment-hong-kongs-city-centre-car
I am not sure how that works with Hong Kong style high rise buildings. I haven't looked into how EV charging is done there.
LOL. You have anything newer than that September article?
China EV policies - shifting from car subsidies to charging infrastructure.
https://www.bloomberg.com/opinion/articles/2019-03-27/china-s-closing-the-6-trillion-electric-car-gap
HAIR - wreckage continues. Perhaps it needs to revisit 0.35. On a proforma basis shares were selling at a MC to sales ratio of 1 at around 0.68 (EV/sales lower because of financing). So at 0.35 it would be selling near 0.5 MC/sales. For services that has upper 60s gross margins and growing. Perhaps TGDT doesn't apply here.
EYPT - down 17% on $20M equity financing at 1.90. The good visibility on Yutiq uptake must be slow looking. Dexycu for cataract surgery is a bigger market.
http://www.biotuesdays.com/briefs/2019/3/28/eyepoint-pharma-prices-20-million-stock-offering
Nice review of SOC for glioblastoma. TTF hasn't made the list yet.
https://www.scientificamerican.com/article/new-strategies-take-on-the-worst-cancer-glioblastoma/
Speaking of HBV. Any thoughts RE slow launch at DVAX and current valuation?
E-planes coming soon to Seattle and Vancouver for island hopping. Another example of where economics dictate change, not climate policy. CVX is current kerosene supplier for these flights.
https://www.bloomberg.com/news/articles/2019-03-26/canada-seaplane-operator-harbour-air-plans-electric-engine-flight?srnd=hyperdrive
Yeah. I recall what Lee Raymond said about climate change, nobody is going to do anything about it. Short term economics will dictate, not policy.
I think you pasted the wrong link.
RE shale production decline. CEO panel discussion. I am not sure if these CEO's are really that ignorant or just pretending to be. Interference is as old as wildcatting, just look up the history of East Texas field. Scale and timing are different because the permeability is lower and heterogeneity maybe different. Notice that Encana CEO said they see no issue and the reason, IMO, is that they have bigger resource position and bigger spatial volume to work with. That is all. If an independent's CEO has to fumble their way through interference questions, that is a yellow flag. For conventional reservoirs, one would implement secondary or EOR. Like what OXY and DNR have been doing.
https://www.spe.org/en/jpt/jpt-article-detail/?art=5225
HAIR - PR this morning regarding solo procedure by Weill Cornell dermatologist. Second link is what is required for Neograft system if doctor does not have his/her own specialised staff. Venus offers specialised staffing as fee for service.
https://restorationroboticsinc.gcs-web.com/news-releases/news-release-details/restoration-roboticsr-announces-first-ever-solo-artas-ixtm
https://www.neografters.com/
IMO it is only a matter of time before US major makes move similar to Shell. They need to do it while cash flow from O&G is still big.
~20k per month.
GME - somebody took the CEO job finally, again. Good for another bounce.
https://www.barrons.com/articles/gamestop-has-a-new-ceo-finally-51553205764
Another thought is that ttf company(s) would be more comparable to radiation modalities so valuation process more like varian or elektra. Not sure if there is a pure p-beam company. However, nvcr is not getting push back yet on pricing like cancer drug.
Taking short cuts via TSLA IP if you can get away with it.
https://www.theverge.com/2019/3/21/18275617/tesla-former-employee-lawsuit-trade-secret-theft-zoox-xpeng-feature
ABBV/Roche - halt on anti-MM /bcma trial.
https://endpts.com/roche-abbvie-slam-the-brakes-on-myeloma-studies-of-star-drug-venclexta-after-researchers-flag-higher-risk-of-death/
Saw that. Not sure if any other company would have done the PR differently to avoid looking like protesting too much. It is what it is, perhaps aacr committee should put a limit on presentations on one topic and hurt some feelings.
Just to clarify, o-USA would still require something like 510K process whereas the US would require PMA? I am cautious about Zlab ultimately being the competitor rather than partner.
I guess the merger must be really detested because of the weighting of the slow growth derm side initially. I see that as a steady business that will finance the hair transplant robotics side. Moll has had one clunker that was Hansen. Even there he rolled the shareholders into Auris that was recently purchased by JNJ. He has generally been aligned to shareholders if you held long enough. ISRG, MAKO and Auris are examples although he sold too early in ISRG personally.
True and also makes for a good test site. It is now a dead horse as well.
I am more interested in how to value it (nvcr or company X) vs cancer drug. How to think about in terms of response range (thinking that it cannot achieve CR unless in a combo with drug). How to think about barrier to entry. etc to come up with value.
Somewhat related. A question about how to value device vs drug companies. For example TTF vs PD1 or PDL1 where TTF has the same or higher level of efficacy as I/O for some indications such as GBM.
http://cancerres.aacrjournals.org/content/77/13_Supplement/3665
AFMD +7% on ROCK milestone payment from Roche.
https://www.affimed.com/wp-content/uploads/20190319_afmd_ROCK-milestone_final.pdf
More on oil demand impact from BNEF. EV passenger cars won't have an impact for a while. However, impact from non passenger EV has started. Waste management has rolled out E garbage trucks in our town and I really appreciate their quietness. I don't know they are here until I hear the dumping of the garbaging bins compare to the deisel days when you can hear them all day long since they have seperate trucks for green, recycle and trash waste. Regional buses already run on CNG so no impact there on diesel demand. However, school buses are all diesel and those will switch over soon IMO.
https://www.bloomberg.com/news/articles/2019-03-19/forget-tesla-it-s-china-s-e-buses-that-are-denting-oil-demand
NYC fleet analysis of total cost of ownership, BEV vs PHEV vs ICE cars.
https://qz.com/1571956/new-york-city-says-electric-cars-cheapest-option-for-its-fleet/
"PR stunt" would be the response from competition that will now have to do the same PR stunt while there are selfie taking peds and a few garbage cans. Reporter obviously was quite nervous going full speed on Grant St. If you have ever driven those SF roads, you would know the concentration level required to drive those roads safely. I hated driving there.
I doubt it. More details in the article about pedestrians and wind blown "obstacle" being avoided in the Lombard St drive where reporter was passenger. Those are impossible to stage. Six way intersection is also impossible to stage. I think I know where the latter one is as I do bike rides along there on occasion.
ZOOX - A self driving startup demo'd hands off navigation of Lombard St in SF and 6-way intersection (probably somewhere along the harbor near pier 39).
https://www.bloomberg.com/news/articles/2019-03-18/zoox-can-cruise-san-francisco-without-drivers-now-it-needs-money?srnd=hyperdrive
HAIR - analysts downgrades this AM. Reasons discussed in link. Only found Cutera (CUTR) as a comparable to pre-merger Venus. Most derm laser companies are either private or small part of med device company (Cynosure inside of HOLX for example). The laser hardware business is tough as Dew has mentioned. Cutera's GM is in the 45% range. Venus has a different model and has GM at 70% as they focus more on sales, disposables, service and finance side of business and let Lumenis and Syneron be the manufacturing/lab. Blair and Roth analyst sees the dominance of derm on the merger cover page. IMO, merger is really a way to finance the penetration of robotics into hair transplant space and this will do it a lot more rapidly via neograft accts without building a sales force from scratch.
http://www.biotuesdays.com/briefs/2019/3/18/analysts-downgrade-restoration-robotics-after-merger-pact
HAIR - Round trip completed. Got all the shares back. Current 2019 proforma numbers - 19M shares outstanding (1:15 reverse split adjusted), 130-135M revenues, gross margin 60%+. Dermatology revenues in 2018 ~$100M.
Venus Concept purchased Neograft (handheld FUE workstation) only a year ago and switched to subscription model in late 2018.
What is your time horizon in years for "medium term"?
First mention of EV's on this board was back in December 2015.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118940053
HAIR - looks like it will end up only +20% or so for the day. Pre-market got up to 100%+. I guess the numbers, equity financing and convoluted reverse merger move are confounding. I see HAIR being on the Roth conference agenda. Not sure if they will still go to present or not. Using 135M 2019 proforma revenues at 60% GM should get us a higher valuation using proforma shares outstanding of 19M post stock split (15 to 1 reverse). I see the hair robotics portion generating a hefty bottom line with the displacement of old neograft workstations in several years if not shorter. Why suffer fools?
Sold a small portion today intending to get it back.
Ps. bought back half of what I sold. That was quick! Not quite as low as what Fred Moll got but close enough.
The ER CC turned out to be all about the merger. A lot of it about Artas penetration via established Neograft accounts. Makes sense. Not much talk about derm business. IMO they will rationalised subscription lines once penetration of Artas gets going. Still need CE Mark for EU and I don;t foresee any problems getting that done.
https://edge.media-server.com/m6/p/iuq76z2b
Thanks. Agree I think the obsolescence issue always weighs on the equipment buyer on top of high capital cost - just like the doctors that bought the first version of HAIR's system. The subscription model makes more sense on both sides if the system improves productivity sufficiently. Merger slide deck has additional info.
https://restorationroboticsinc.gcs-web.com/static-files/32bd3029-0ff3-4450-a556-a574855238a9
HAIR - Neograft was the obsoleted equipment that Venus Concept offered prior to merger. I can see why they wanted HAIR. Lots of existing (all) transplant doctors currently using that so it should be an easy path to substitution if they are already on subscription.
On the dermatology side, Venus appears to have taken over the technology from Syneron and Lumenis. Syneron was the leader in derm lasers years ago and used to trade on nasdaq.
https://neograft.com/
Here is a brief description of "revenue sharing" model being implemented globally.
https://markets.businessinsider.com/news/stocks/venus-concept-launches-revenue-share-program-in-north-america-and-europe-1027426442